Satellos Bioscience Inc. is making waves with a notable intraday gain of 1.65%, closing at CA$8.65.
In the latest trading session, Satellos Bioscience Inc. (MSCL.TO) saw its stock price rise by 1.65%, reflecting positive investor sentiment. This uptick comes as the company continues to advance its clinical trials and explore new avenues for growth.
Investor takeaway: Investors may find Satellos Bioscience's focus on innovative treatments for Duchenne muscular dystrophy appealing, especially as the company progresses in its clinical trials.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Satellos Bioscience Inc.
MSCL.TO
MSCL.TO
Satellos Bioscience Inc.
WealthAwesomeMarket cap
$267.68M
52W high
$18.98
52W low
$6.36
1W change
+10.04%
Beta
1.17
Analyst Price Targets
Based on analyst covering MSCL
Wall Street analysts forecast MSCL stock price to rise 39.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$17.67
+39.0% Upside
Current Price
C$12.71
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSCL's historical volatility
30-Day Vol
94.6%
Annualized
90-Day Vol
95.9%
Annualized
Trend (90d)
+27.3%
Annualized drift
90d Mean
C$14.01
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$13.13 | C$9.47 โ C$18.20 |
| 60 trading days | C$13.56 | C$8.55 โ C$21.52 |
| 90 trading days | C$14.01 | C$7.96 โ C$24.66 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Satellos Bioscience Inc. Gains 1.65% in One Day
With a market cap of CA$170.8 million, Satellos's stock performance reflects growing investor interest in its innovative approaches.
Bull case
The recent dosing of the first adult patient in the LT-001 study marks an important step forward for Satellos. This progress could lead to significant breakthroughs in treatment options for Duchenne muscular dystrophy.
Bear case
Despite today's gains, Satellos still faces challenges common in the biotech sector, such as uncertainty around clinical trial outcomes and how the market will respond to its developments.
Recent Developments
Satellos has recently announced the dosing of its first adult patient in the LT-001 study, aimed at evaluating the long-term effects of SAT-3247 for Duchenne muscular dystrophy. This milestone is crucial as it shows the company's commitment to advancing its clinical programs.
Market Performance
The stock's rise to CA$8.65 today reflects a broader interest in biotech stocks, particularly those focusing on rare diseases. With a market cap of CA$170.8 million, investors are closely watching Satellos for potential breakthroughs that could enhance its market position.
Looking Ahead
As Satellos continues its clinical trials, investors should keep an eye on upcoming announcements regarding trial results and further developments in their product pipeline, which could significantly impact stock performance.
Advertisement
